26. HTLV-1-associated myelopathy
26 clinical trials,   46 drugs   (DrugBank: 27 drugs),   37 drug target genes,   123 drug target pathways
Searched query = "HTLV-1-associated myelopathy", "Tropical spastic paraparesis", "HTLV-1", "HTLV-I-associated myelopathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01343355 (ClinicalTrials.gov) | January 2011 | 25/4/2011 | Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) | Open-Label, Exploratory Study of the Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) | HTLV-I-Associated Myelopathy | Drug: Tamibarotene | St. Marianna University School of Medicine | NULL | Active, not recruiting | 30 Years | 75 Years | Both | 15 | Phase 2;Phase 3 | Japan |